Azita Saleki-Gerhardt - 18 Feb 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, CHIEF OPERATIONS OFFICER
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt
Issuer symbol
ABBV
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 18:35:18 UTC
Previous filing
14 Aug 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER 1 N. WAUKEGAN ROAD, NORTH CHICAGO /s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt 20 Feb 2026 0001563545

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Award $0 +17,041 +9.6% $0.000000 194,333 18 Feb 2026 Direct F1
transaction ABBV Common Stock, $0.01 par value Award $0 +6,058 +3.1% $0.000000 200,391 18 Feb 2026 Direct F2
transaction ABBV Common Stock, $0.01 par value Award $0 +7,074 +3.5% $0.000000 207,465 18 Feb 2026 Direct F3
transaction ABBV Common Stock, $0.01 par value Award $0 +6,638 +3.2% $0.000000 214,103 18 Feb 2026 Direct F4
holding ABBV Common Stock, $0.01 par value 2,706 18 Feb 2026 Profit sharing trust F5
holding ABBV Common Stock, $0.01 par value 3,873 18 Feb 2026 By spouse F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Award $0 +20,312 $0.000000 20,312 18 Feb 2026 Common Stock 20,312 $230.04 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F2 Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F3 Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F4 Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F5 Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
F6 The reporting person disclaims beneficial ownership of all securities held by her spouse.
F7 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.